Omega Therapeutics

Yahoo Finance • 10 months ago

24 Least Developed Countries in Europe in 2024

In this article, we will look into the 24 least developed countries in Europe in 2024. If you want to skip our detailed analysis, you can go directly to 5 Least Developed Countries in Europe in 2024. Europe's Economic Outlook Europe is a... Full story

Yahoo Finance • 11 months ago

Novo Nordisk enters into research collaborations with Omega Therapeutics and Cellarity on novel treatment approaches for cardiometabolic diseases

Novo Nordisk A/S Omega collaboration will leverage the company’s platform to develop an epigenomic controller as part of a new approach to obesity management Cellarity collaboration will build upon initial work and engage the company’s pl... Full story

Yahoo Finance • last year

Omega Therapeutics Showcases Bidirectional and Multiplexed Epigenomic Control of Gene Expression in Preclinical Models of Liver Inflammation and Fibrosis

First-ever demonstration of sustained pre-transcriptional upregulation of gene expression by an epigenomic controller in both in vitro and in vivo models of liver fibrosis Single epigenomic controller demonstrated ability to simultaneousl... Full story

Yahoo Finance • last year

Omega Therapeutics Reports Third Quarter 2023 Financial Results and Highlights Recent Company Progress

Announced promising preliminary clinical data for OTX-2002 from ongoing MYCHELANGELO™ I trial; clinical proof-of-platform established with potential applicability across a broad range of diseases Advanced OMEGA platform capabilities and pr... Full story

Yahoo Finance • last year

Omega Therapeutics to Participate in The Jefferies London Healthcare Conference

CAMBRIDGE, Mass., Nov. 07, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today anno... Full story

Yahoo Finance • last year

Omega Therapeutics Presents New Preclinical Data Supporting the Potential of OTX-2101 in Combination Settings for Treatment of NSCLC

CAMBRIDGE, Mass., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today anno... Full story

Yahoo Finance • last year

Omega Therapeutics Announces Two Poster Presentations on Liver Inflammation and Fibrosis at AASLD’s The Liver Meeting® 2023

CAMBRIDGE, Mass., Oct. 11, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today anno... Full story

Yahoo Finance • last year

Omega Therapeutics to Present New Preclinical Data on OTX-2101 at the 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics

CAMBRIDGE, Mass., Oct. 04, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today anno... Full story

Yahoo Finance • last year

Omega Therapeutics Announces Promising Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial

All 8 patients treated with OTX-2002 in initial two cohorts achieved highly specific on-target genomic engagement, intended epigenetic state change and robust downregulation in expression of c-MYC, a historically ‘undruggable’ target Firs... Full story

Yahoo Finance • last year

Omega Therapeutics to Host Conference Call to Discuss Preliminary Clinical Data for OTX-2002 from Ongoing MYCHELANGELO™ I Trial on September 26

CAMBRIDGE, Mass., Sept. 25, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today ann... Full story

Yahoo Finance • last year

Omega Therapeutics to Participate in Two Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 21, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today ann... Full story

Yahoo Finance • last year

Omega Therapeutics Announces Updates to its Board of Directors

Chris Schade to Assume Role of Chairman of the Board, Succeeding Noubar Afeyan, Ph.D.Michelle C. Werner, CEO of Alltrna, Appointed to Board of Directors CAMBRIDGE, Mass., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasda... Full story

Yahoo Finance • last year

Omega Therapeutics Appoints Chris Schade to its Board of Directors

CAMBRIDGE, Mass., July 12, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today anno... Full story

Yahoo Finance • 2 years ago

Flagship Pioneering Launches Metaphore Biotechnologies to Unlock the Therapeutic Potential of Biomimicry

The company's MIMiC™ platform drives unprecedented insights into molecular interactions to design new biomolecules precisely tuned for therapeutic benefit With $50 million in committed capital from Flagship, Metaphore has built a first-in... Full story

Yahoo Finance • 2 years ago

Omega Therapeutics Reports First Quarter 2023 Financial Results and Highlights Recent Company Progress

Continued to Advance Monotherapy Dose Escalation Stage of Ongoing Phase 1/2 MYCHELANGELO™ I Study; Preliminary Data Anticipated in 2023Announced Clinical Supply Agreement with Roche to Evaluate OTX-2002 in Combination with Atezolizumab in... Full story

Yahoo Finance • 2 years ago

Omega Therapeutics to Present New Preclinical Data at the American Society of Clinical Oncology 2023 Annual Meeting

CAMBRIDGE, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenomic mRNA medicines, today ann... Full story

Yahoo Finance • 2 years ago

Omega Therapeutics Announces Clinical Supply Agreement to Evaluate the Combination of OTX-2002 and Atezolizumab in Hepatocellular Carcinoma

CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today ann... Full story

Yahoo Finance • 2 years ago

Omega Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

Advanced Company’s Lead Program, OTX-2002, in the Clinic; Preliminary Data from Phase 1/2 MYCHELANGELO™ I Trial Anticipated in 2023 Progressed IND-enabling Studies for OTX-2101; Company’s Development Candidate for MYC-driven Non-Small Cel... Full story

Yahoo Finance • 2 years ago

Omega Therapeutics Announces $40 Million Registered Direct Offering of Common Stock

CAMBRIDGE, Mass., Feb. 23, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the development of a new class of programmable epigenetic mRNA medicines, today anno... Full story

Yahoo Finance • 2 years ago

Charles River and Flagship’s Pioneering Medicines Enter Agreement Leveraging AI-Powered Logica with Aim of Creating Novel Therapies for Unmet Medical Needs

Logica, an offering from Charles River and Valo Health will be deployed by Pioneering Medicines across a portfolio of targets WILMINGTON, Mass. & CAMBRIDGE, Mass., February 16, 2023--(BUSINESS WIRE)--Charles River Laboratories Internation... Full story